MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*”Architects”: Geriatrics, Gerontology, Geroscience, Longevity, Healthspan & Aging
BioAge Labs, Inc. (BIOA)
Organization & Developments: BioAge Lab
Parents
BioAge Labs, Inc. (BIOA)
Children
*The BioAge mission is to extend healthy lifespan by developing treatments that target the molecular causes of human aging.
2024: BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
2024: BioAge Labs Readies $135 Million U.S. IPO To Advance Obesity Treatments
2024: BioAge prices $198M IPO, validating pivot to obesity drug research
2024: BioAge scraps mid-stage trial of experimental obesity drug, shares fall
2024: Novartis, BioAge take on age-related diseases in $550M pact
2025: BioAge axes obesity asset over liver toxicity, pivots to preclinical prospects
2025: Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential_ seekingalpha.com
2026: BioAge pill to reduce heart risks significantly reduced inflammation
Jumps
Finance & Acquisitions: BioAge Lab
Key People: BioAge Lab